Cost-effectiveness analysis in colorectal cancer using a semi-Markov model

Statistics in Medicine

Volumn 26, Issue 30, 2007, Pages 5557-5571

  Castelli, Christel ^a   Combescure, Christophe ^a,b   Foucher, Yohann ^a   Daures, Jean Pierre ^a,b  

^a UNIV MONTPELLIER   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Cost effectiveness; INB; Regression; Semi Markov model

Indexed keywords

AGED; BOOTSTRAPPING; CANCER RELAPSE; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COVARIANCE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; PROBABILITY; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COLORECTAL SURGERY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NEOPLASM STAGING; PERSONAL HEALTH SERVICES; POSTOPERATIVE PERIOD; PROBABILITY THEORY; RECURRENCE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 38849191739     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3112     Document Type: Conference Paper

References (25)

1. Austin PC, Ghali WA, Tu JV. A comparison of several regression models for analysing cost of CABG surgery. Statistics in Medicine 2003; 22:2799-2815.
2. Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Statistics in Medicine 2005; 24:131-145.
3. Liu L, Wolfe RA, Kalbfleisch JD. A shared random effects model for censored medical costs and mortality. Statistics in Medicine 2007; 26:139-155.
4. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometric 1997; 53:419-434.
5. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical Decision Making 1993; 13:322-338.
6. Gardiner JC, Luo Z, Liu L, Bradley CJ. A stochastic framework for estimation of summary measures in cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research 2006; 6:347-358.
7. Gardiner JC, Luo Z, Bradley CJ, Sirbu CM, Given CW. A dynamic model for estimating changes in health status and costs. Statistics in Medicine 2006; 25(21):3648-3667.
8. Papadopoulou AA, Vassiliou PCG. Semi-Markov Models and Applications, Chapter 15. Kluwer Academic Publishers: Dordrecht, 1999; 241-251.
9. Karlin S, Taylor HM. A First Course in Stochastic Processes, Chapter 4 (2nd edn). Academic Press: New York, 1975.
10. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models Based on Counting Processes. Springer: Berlin, 1993.
11. Foucher Y, Mathieu E, Saint-Pierre P, Durand JF, Daures JP. A Semi-Markov model based on generalized Weibull distribution with an illustration for HIV disease. Biometrical Journal 2005; 47:825-823.
12. Siani C, Moatti JP. Quelles méthodes de calcul des régions de confiance du ratio coût-efficacité incrémental choisir? Revue d'Epidémiologie et de Santé Publique 2003; 51:255-276.
13. Perez-Ocon R, Ruiz-Castro JE. Semi-Markov Models and Applications, Chapter 14. Kluwer Academic Publishers: Dordrecht, 1999; 229-238.
14. Wang H, Zhao H. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data. Biometrics 2006; 62:570-575.
15. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Economics 1997; 6:243-252.
16. Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 2001; 57:1002-1008.
17. Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research 2001; 1:25-36.
18. Craig BA, Black MA. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin. Expert Review of Pharmacoeconomics and Outcomes Research 2001; 1(1):37-46.
19. Tambour M, Zethraeus N. Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results. Health Economics 1998; 7:143-147.
20. O'Hagan A, Stevens JW. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality. Health Economics 2003; 12:33-49.
21. Borie F, Combescure C, Daurès JP, Trétarre B, Millat B. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model. World Journal of Surgery 2004; 28:563-569.
22. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996; 15:1447-1458.
23. Duan N. Smearing estimate: a nonparametric retransformation method. Journal of the American Statistical Association 1983; 79:605-610.
24. Aguirre-Hernandez R, Farewell VT. A Pearson-type goodness-of-fit test for stationary and time-continuous Markov regression models. Statistics in Medicine 2002; 21:1899-1911.
25. Baser O, Gardiner JC, Bradley CJ, Yuce H, Given C. Longitudinal analysis of censored medical cost data. Health Economics 2006; 15:513-525.